BridgeBio Pharma BBIO 深 沪
已收盘 12-19 16:00:00 美东时间
76.28
+2.140
+2.89%
华盛通- 最 高77.20
- 今 开74.44
- 成交量 178.87万股
- 最 低 69.53
- 昨 收 74.14
- 总市值 112.89亿
- 52周最高 77.20
- 市盈率 静 --
- 换手率 1.21%
- 52周最低 27.23
- 委 比 12.83%
- 总股本 1.48亿
- 历史最高 77.20
- 量 比 1.07
- 振 幅 10.35%
- 历史最低 1.10
- 每 手 1
- 风险率 12.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多药捷安康，惊心动魄的事总在发生。。。
（来源：成长企业常识） 后浪森林研究室 | 洛上洲 惊心动魄的事总在发生，且就发生在公众眼前，且就在一两天的极短时间内，几百、几千亿的财富比泡沫更膨胀...
09-17 08:02
BridgeBio(BBIO.US)指控辉瑞(PFE.US)、Alnylam(ALNY.US)在数十亿美元心脏病药市场采用“争议策略”竞争
BridgeBio Pharma(BBIO.US)正凭借一款心脏病药物与辉瑞(PFE.US)、Alnylam Pharmaceuticals(ALNY.US)展开竞争。该公司称其药物疗效更优且成本更低，但同时指控竞争对手在这个价值数十亿美元的市场中采用“有争议的策略”进行竞争。 争议焦点源于辉瑞本月在一场医学会议上播放的一段视频——视频中称其药物Vyndamax是治疗某类致命性心力衰竭的“首款且唯一获批疗法”，却刻意隐瞒了两项关键事实：BridgeBio的竞品药物已于2024年11月上市，而Alnylam的同类药物自今年3月起也已投入使用。BridgeBio首席执行官尼尔·库马尔(Neil K...
09-12 08:27
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
BridgeBio Pharma管理层将参加高盛第46届年度全球医疗健康大会炉边访谈环节，会议时间为2025年6月9日。可通过BridgeBio投资者页面访问直播或30天内回看。BridgeBio是一家专注开发治疗遗传病的改变游戏规则药物的生物制药公司。
06-02 11:30
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Boundless Bio announces portfolio prioritization focusing on BBI-355 and BBI-825 combination therapy, and BBI-940 for its Kinesin program. The company extends its cash runway into early 2028, discontinues certain clinical trial arms, and plans to initiate new trials in 2025. A webcast on May 27 will provide further details.
05-23 20:01
DeepSeek爆火，医药行业的AI革命与“降本增效”新叙事
2025年2月，中国AI企业深度求索（DeepSeek）的开源大模型DeepSeek-R1在资本市场掀起巨浪。其技术突破与低成本优势，不仅吸引了亚马逊AWS、微...
02-12 20:08
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study demonstrated increased cortisol production and reductions in key biomarkers. BridgeBio plans to seek partners for further development.
2024-09-12 01:44
Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $70 price target.
2024-09-09 23:24
Piper Sandler Initiates Coverage On BridgeBio Pharma with Overweight Rating, Announces Price Target of $46
Piper Sandler analyst Biren Amin initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Overweight rating and announces Price Target of $46.
2024-09-04 22:37
Piper Sandler Initiates BridgeBio Pharma at Overweight
05:47 AM EDT, 09/04/2024 (MT Newswires) -- BridgeBio Pharma (BBIO) has average rating of buy and price targets ranging from $37 to $70, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia ...
2024-09-04 17:47
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Nasdaq Composite falling around 2% on Tuesday. Shares of Vaxcyte, Inc. (NASDAQ:PCVX) rose sharply during Tuesday's session after the company released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the compan...
2024-09-03 22:47
